Allevi Author: Allevi and Dr. Anthony Atala

Allevi Author publication

With a 12% success rate for drugs entering clinical trials, there is no doubt that drug companies need more accurate prediction platforms to help them save billions in bringing a drug to market. 3D cellular models, such as spheroids, organoids and organ-on-chips, offer a promising solution to this issue. But how can these models be built at the complexity and scale needed for pharma? Bioprinting’s ability for increased complexity and automation is the clear answer.

Read our co-authored paper with Dr. Anthony Atala, Director of the Wake Forest Institute for Regenerative Medicine (WFIRM) and featured on TED, describing the potential of bioprinting to improve drug testing. 

“Bioprinted organoids can potentially provide significant benefits to drug companies and patients alike,” said Atala. “More accurate and faster testing brings new drugs to market sooner, and the possibility of engineering tumors in the lab from a patient’s own cells mean patients can get the best therapy right away – without time spent taking therapies that won’t work for them.”